262: Merck v. USA, the best of ASCO, and Leqembi at the FDA
b'STAT Washington correspondent Rachel Cohrs joins us to explain Merck\'s lawsuit against the federal government and why the company believes drug pricing negotiation is \\u201ctantamount to extortion." We also discuss the health effects of Canadian wildfires, the highlights of the year\\u2019s biggest cancer research conference, and what could be a watershed moment in the treatment of Alzheimer\\u2019s.'